Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Recombinant Human Growth Hormone and/or Rosiglitazone in the Treatment of Human Immunodeficiency Virus-Associated Visceral Adiposity and Insulin Resistance

Trial Profile

Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Recombinant Human Growth Hormone and/or Rosiglitazone in the Treatment of Human Immunodeficiency Virus-Associated Visceral Adiposity and Insulin Resistance

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Apr 2016

At a glance

  • Drugs Rosiglitazone (Primary) ; Somatropin (Primary)
  • Indications HIV-associated lipodystrophy syndrome; Insulin resistance
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Apr 2016 New trial record
    • 01 Mar 2016 Results of a substudy published in the HIV Clinical Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top